Skip to main content Accessibility help
×
Home

The Treatment of Acute Agitation in Schizophrenia

  • Joseph Battaglia (a1), Delbert G. Robinson (a2) and Leslie Citrome (a3)

Abstract

Acute agitation is a nonspecific term applied to an array of syndromes and behaviors. It is frequently defined as an increase in psychomotor activity, aggression, disinhibition/impulsivity, and irritable or labile mood. Etiologies of acute agitation include medical disorders, delirium, substance intoxication or withdrawal, psychiatric disorders, and medication side effects. Treatment of acute agitation requires both environmental and pharmacologic intervention. Patients should be calmed with sedating agents early in the course of treatment, allowing for diagnostic tests to take place. Failure to correctly diagnose causes of agitation may lead to delayed treatment for serious conditions, and can even exacerbate agitation.The most common cause of agitation in patients with schizophrenia is psychotic relapse due to medication nonadherence. Pharmacologic treatment options for these patients include lorazepam and antipsychotic agents. Lorazepam causes nonspecific sedation and treats some substance withdrawal, but has little effect on psychosis. First-generation antipsychotics treat psychosis and, at high enough doses, cause sedation, but may induce extrapyramidal side effects (EPS). Some second-generation antipsychotics have been approved for the treatment of agitation in schizophrenia. These agents treat psychosis with a favorable EPS profile, but are comparatively expensive and cause risks such as hypotension. However, avoiding EPS may reduce patients' resistance to antipsychotic treatment.

In this expert roundtable supplement, Joseph Battaglia, MD, provides an overview of the definition of acute agitation. Next, Delbert, G. Robinson, MD, outlines evaluation methods for actue agitation. Finally, Leslie Citrome, MD, MPH, reviews interventions for acute and ongoing management of agitation.

Copyright

References

Hide All
1.Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 2000.
2.RH, Swift, Harrigan, EP, Cappelleri, JC, Kramer, D, LP, Chandler. Validation of the Behavioral Activity Rating Scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36(2):8795.
3.Yudofsky, SC, Kopecky, HJ, Kunik, M, Silver, JM, Endicott, J. The Overt Agitation Scale for the objective rating of agitation. J Neuropsychiatry Clin Neurosci. 1997;9(4):541548.
4.Wolthaus, JE, Dingemans, PM, Schene, AH, et al.Component structure of the positive and negative syndrome scale (PANSS) in patients with recent-onset schizophrenia and spectrum disorders. Psychopharmacology (Berl). 2000;150(4):399403.
5.Kay, SR, Sevy, S. Pyramidical model of schizophrenia. Schizophr Bull. 1990;16(3):537545.
6.Wright, P, Birkett, M, David, SR, et al.Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158(7):11491151.
7.Best, M, Williams, MJ, Coccaro, EF. Evidence for a dysfunctional prefrontal circuit in patients with an impulsive aggressive disorder. Proc Natl Acad Sci U S A. 2002; 99(12):84488453.
8.Quanbeck, CD, McDermott, BE, Lam, J, et al.Categorization of aggressive acts committed by chronically assaultive state hospital patients. Psychiatr Serv. 2007;58(4):521528.
9.Schatzberg, AF, DeBattista, C. Phenomenology and treatment of agitation. J Clin Psychiatry. 1999;60(suppl 15):1720.
10.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:5662.
11.Montgomery, SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382389.
12.Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429435.
13.Center for Medicaid and Medicare Services. Definition of Chemical Restraint: January 2007. Regulation 483.
1.Hazlett, SB, McCarthy, ML, Lindner, MS, Onyike, CU. Epidemiology of adult psychiatric visits to US emergency departments. Acad Emerg Med. 2004;11:193195.
2.Owen, C, Tarantello, C, Jones, M, Tennant, C. Repetitively violent patients in psychiatric units. Psychiatr Serv. 1998;49:14581461.
3.McNiel, DE, Binder, RL, Greenfield, TK. Predictors of violence in civilly committed acute psychiatric patients. Am J Psychiatry. 1988;145:965970.
1.Citrome, L, Volavka, J. Treatment of Violent Behavior. In: Tasman, A, Lieberman, J, Kay, J, eds. Psychiatry. 2nd ed. John Wiley & Sons, Ltd; 2003:21362146.
2.Citrome, L, Nolan, KA, Volavka, J. Science-based treatment of aggression and agitation. In Fishbein, D, ed. The Science, Treatment, and Prevention of Antisocial Behaviors, Volume 2. Kingston, New Jersey: Civic Research Institute, Inc; 2004.
3.Citrome, L, Volavka, J. Clinical management of persistent aggressive behavior in schizophrenia: Part I Definitions, epidemiology, assessment, and acute treatment. Essent Psychopharmacol. 2002;5:116.
4.Citrome, L. Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Postgrad Med. 2002;112(6):85–8, 9496.
5.Citrome, L. Intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: equipoise or not?J Clin Psychiatry. In press.
6.Daniel, DG, Potkin, SG, Reeves, KR, et al.Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology (Berl). 2001;155:128134.
7.Lesem, MD, Zajecka, JM, Swift, RH, et al.Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001;62:1218.
8.Tran-Johnson, TK, Sack, DA, Marcus, RN, et al: Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double- /blind, placebo-controlled trial. J Clin Psychiatry. 2007;68:111119.
9.Wright, P, Birkett, M, David, SR, et al.Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158(7):11491151.
10.Breier, A, Meehan, K, Birkett, M, et al.A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59(5):441448.
11.Meehan, K, Zhang, F, David, S, et al.A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21:389397.
12.Andrezina, R, Josiassen, RC, Marcus, RN, et al.Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl). 2006;188:281292.
13.Zimbroff, DL, Marcus, RN, Manos, G, et al.Management of acute agitation in patients with bipolar disorder. Efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. 2007;27:171176.
14. Geodon (ziprasidone HCl) capsules, Geodon (ziprasidone mesylate) for injection for IM use only. New York, NY: Pfizer; 2007.
15. Zyprexa (olanzapine) tablets, Zyprexa Zydis (olanzapine) orally disintegrating tablets, Zyprexa IntraMuscular (olanzapine) for injection. Indianapolis, IN: Eli Lilly; 2006.
16. Abilify (aripiprazole) tablets, Abilify (aripiprazole) DiscMelt orally disintegrating tablets, Abilify (aripiprazole) oral solution, Abilify (aripiprazole) injection. Jacksonville, FL: Bristol-Myers Squibb; 2006.
1.Battaglia, J, Moss, S, Rush, J, et al.Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997;15:335340.
2.Meehan, KM, Wang, H, David, SR, et al.Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26:494504.
3.Nolan, KA, Citrome, LL, Saito, K, Xu, J. Reducing Inpatient Aggression: Paying Attention Pays Off. Poster Presented at: The 25th Congress of the Collegium International Neuropsychopharmacologicum; July 2006; Chicago, IL. Abstract in Int J Neuropsychopharmacol. 2006;9(Suppl 1):S150.

The Treatment of Acute Agitation in Schizophrenia

  • Joseph Battaglia (a1), Delbert G. Robinson (a2) and Leslie Citrome (a3)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed